Breaking News

Tweet TWEET

Keryx Biopharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference

Keryx Biopharmaceuticals to Present at the 16th Annual BIO CEO & Investor
Conference

Presentation Scheduled for Monday, February 10th at 4:00pm ET

NEW YORK, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive
Officer, will be presenting at the 16^th Annual BIO CEO & Investor Conference,
to be held February 10-11, 2014, at the Waldorf Astoria Hotel in New York
City. Mr. Bentsur's presentation will take place on Monday, February 10^th, at
4:00pm ET.

A live audio webcast of Mr. Bentsur's presentation will be accessible within
the Investor Relations section of the Company's website at
http://www.keryx.com/webcasts-presentations. An archived version of this
webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex^TM (ferric citrate
coordination complex), an oral, ferric iron-based compound. Zerenex has
completed a U.S.-based Phase 3 clinical program for the treatment of
hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney
disease on dialysis, conducted pursuant to a Special Protocol Assessment
("SPA") agreement with the FDA. Keryx's New Drug Application ("NDA"),
submitted to the FDA in 2013, is currently under review and has an assigned
Prescription Drug User Fee Act ("PDUFA") goal date of June 7, 2014. Zerenex
has also completed a Phase 2 study in the U.S. for the management of elevated
serum phosphorus levels and iron deficiency anemia in patients with Stage 3 to
5 non-dialysis dependent chronic kidney disease. Top-line results from this
Phase 2 study were announced in November 2013. In addition, Keryx's Japanese
partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd., received
marketing approval of ferric citrate in Japan for the treatment of
hyperphosphatemia in patients with chronic kidney disease on January 17,
2014. Keryx is headquartered in New York City.

CONTACT: KERYX CONTACT:
         Lauren Fischer
         Director - Investor Relations
         Keryx Biopharmaceuticals, Inc.
         Tel: 212.531.5965
         E-mail: lfischer@keryx.com

Keryx Logo
 
Press spacebar to pause and continue. Press esc to stop.